



Grünenthal GmbH

EUR 400,000,000 3.625% Senior Secured Notes due 2026
XS2337064856 and XS2337065077
EUR 550,000,000 4.125% Senior Secured Notes due 2028
XS2337703537 and XS2337703610
EUR 300,000,000 6.750% Senior Secured Notes due 2030
XS2615562274 and XS2615563082

Aachen, 22nd March 2024

Dear Sir or Madam,

Today, Grünenthal, the leading innovator in pain treatments, has released its results for the full year ended December 31, 2023. Please find the Operating and Financial Review and the Earnings Presentation for FY 2023 on Grünenthal's Creditors Domain ([Creditors domain | Grünenthal \(grunenthal.com\)](https://creditors.domain.grunenthal.com)).

Kindest regards,

Andrew Duncan
Deputy Head of Treasury and
Head of Investor Relations

Anna Carduck
Investor Relations Manager

creditor-relations@grunenthal.com

Grünenthal Pharma GmbH & Co. KG
52099 Aachen | Germany
www.grunenthal.com
careers.grunenthal.com



Grünenthal
Think Innovation.
Feel Life.®